Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
Characteristics of Sorafenib Therapy
| Characteristic | CrCl ≤ 60 mL/min (n = 14) |
CrCl > 60 mL/min (n = 18) |
|---|---|---|
| Duration, Months | ||
| Median | 2.9 | 3.4 |
| Mean | 3.9 | 4.6 |
| Minimum | 0.7 | 0.9 |
| Maximum | 15.1 | 17.4 |
| Dose Interruptions, Number of Interruptions | ||
| 0 | 6 | 13 |
| 1 | 4 | 2 |
| 2 | 3 | 1 |
| 3 | 0 | 2 |
| 6 | 1 | 0 |
| Dose Reductions, Number of Reductions | ||
| 0 | 8 | 14 |
| 1 | 4 | 4 |
| 2 | 1 | 0 |
| 4 | 1 | 0 |
| Reason for Discontinuation | ||
| Disease progression, n | 10 | 12 |
| Toxicity, n | 2 | 2 |
| Other, n | 1 | 1 |
| Still on sorafenib, n | 1 | 3 |
Abbreviation: CrCl = creatinine clearance
